Biogen (BIIB) Has ~$20-$25 Downside on Negative Ruling - Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Biogen (BIIB) Tecfidera Reduction Impact ~$20/Share - RBC
June 18, 2020 9:49 AM EDTRBC Capital analyst Brian Abrahams weighed in on Biogen (NASDAQ: BIIB) after a judge ruled that Mylan has demonstrated that the asserted claims of BIIB's key '514 patent are invalid for lack of written description.
"While Mylan could launch at risk, we... More
Biogen (BIIB) Tecfidera Patent Invalidated in Mylan (MYL) Dispute - Bloomberg
June 18, 2020 9:03 AM EDTBiogen (NASDAQ: BIIB) Tecfidera Patent Invalidated in Mylan (NASDAQ: MYL) Dispute - Bloomberg
... More